Document:

exv10w3

 

Exhibit 10.3

June 6, 2007

Halifax Corporation

5250 Cherokee Avenue

Pursuant to a subordination agreement dated March 6, 2002 between Provident Bank and the
subordinated debt holders, Research Industries, further assigned on June 29, 2005 to the Arch C.
Scurlock Children’s Trust, the maturity date of the remaining principal balance of $500,000 on the
8% promissory notes plus accrued interest thereon are extended to July 1, 2009.

All other terms and conditions of the notes remain the same.

Dated this 6th day of June 2007

The Arch C. Scurlock Children’s Trust

	 	 	 	 	 
	/s/ Nancy M. Scurlock 

	 	 	 	 
	Nancy M. Scurlock, Trustee

	 	Arch C. Scurlock, Jr., Trustee	 	 
	 
	 	 	 	 
	/s/ Mary Scurlock Adamson
	 	 	 	 
	 

	 	 	 	 
	Mary Scurlock Adamson, Trustee

	 	John H. Grover Trustee	 	 
	 
	 	 	 	 
	/s/ Joseph Sciacca

	 	6/29/07	 	 
	 

	 	 	 	 
	HALIFAX CORPORATION

	 	DATE	 	 
	Joseph Sciacca, CFO
	 	 	 	 

 

 

June 6, 2007

Halifax Corporation

5250 Cherokee Avenue

Pursuant to a subordination agreement dated March 6, 2002 between Provident Bank and the
subordinated debt holders, Research Industries, further assigned on June 29, 2005 to the Arch C.
Scurlock Children’s Trust, the maturity date of the remaining principal balance of $500,000 on the
8% promissory notes plus accrued interest thereon are extended to July 1, 2009.

All other terms and conditions of the notes remain the same.

Dated this 29th day of June 2007

The Arch C. Scurlock Children’s Trust

	 	 	 	 	 
	 

Nancy M. Scurlock, Trustee

	 	/s/ Arch C. Scurlock
 

Arch C. Scurlock, Jr., Trustee
	 	 
	 
	 	 	 	 
	 

	 	/s/ John H. Grover 	 	 
	 

	 	 	 	 
	Mary Scurlock Adamson, Trustee

	 	John H. Grover Trustee	 	 
	 
	 	 	 	 
	/s/ Joseph Sciacca

	 	6/29/07	 	 
	 

	 	 	 	 
	HALIFAX CORPORATION

	 	DATE	 	 
	Joseph Sciacca, CFOexv10w4

 

Exhibit 10.4

June 6, 2007

Halifax Corporation

5250 Cherokee Avenue

Pursuant to a subordination agreement dated March
6, 2002 between Provident Bank and the subordinated
debt holders, Research Industries, further assigned on
June 29, 2005 to Nancy Morrison Scurlock, the maturity
date of the remaining principal balance of $500,000 on
the 8% promissory notes plus accrued interest thereon
are extended to July 1, 2009.

All other terms and
conditions of the
notes remain the
same.

Dated this 6th day of June 2007

	 	 	 	 	 
	/s/ Nancy Morrison Scurlock
	 	 	 	 
	Nancy Morrison Scurlock	 	 	 	 
	 
	 	 	 	 
	/s/ Joseph Sciacca
 

HALIFAX CORPORATION

	 	6/29/07
 

DATE
	 	 
	Joseph Sciacca, CFOexv4w1w4d

 

Exhibit 4.1.4d

FOURTH AMENDMENT TO

WARRANT TO PURCHASE COMMON STOCK

     THIS AGREEMENT amends and forms a part of the Warrant to purchase Common Stock dated May 23,
2001 (“Warrant”), by and between IdleAire Technologies Corporation (the “Company”) and Lana Batts.

     The parties agree that the Warrant is hereby amended as follows:

     1. Section I, “Term of Warrant,” is revised to read as follows:

     This warrant
may be exercised at any time after May 23, 2001, but before the earlier of May
23, 2008 or the date on which the Company completes an initial public offering, merger or other
event that would give rise to a “voluntary conversion” or “mandatory conversion”
of shares of the
Company’s Series B convertible preferred stock, as defined
in Section III, page 15, of the Company’s
Series B Convertible Preferred Stock Confidential Private Placement Memorandum dated November 2003.

     2. In all other respects, the original terms and conditions of the Warrant shall remain in
full force and effect.

      
    IN WITNESS WHEREOF, the parties have executed this Third Amendment as of the 13th day of May
2006.

	 	 	 	 	 
	IDLEAIRE TECHNOLOGIES CORPORATION
	 
	 	 	 	 
	By:

	 	/s/ Paul Boyd	 	 
	 

	 	 	 	 
	Name:

	 	Paul Boyd	 	 
	Its:

	 	Cfo & Treasurer	 	 
	 
	 	 	 	 
	/s/ Lana Batts	 	 
	 	 	 
	Lana Battsexv10w1

 

Exhibit 10.1

AMENDMENT NO. 1 TO

THE BOARD REPRESENTATION AND

GOVERNANCE AGREEMENT

     This AMENDMENT NO. 1 (the “Amendment”) to the Board Representation and Governance Agreement
(the “Board Representation and Governance Agreement”), dated as of June 22, 2007, by and between
Intervoice, Inc., a Texas corporation (the “Company” or “Intervoice”) and David W. Brandenburg, a
natural person residing in the State of Florida (“David Brandenburg”), is being entered into as of
July 1, 2007.

     WHEREAS, on July 1, 2007, Daniel D. Hammond resigned as a member of the Company’s Board of
Directors (the “Company Board”) and any committee thereof, indicated that he no longer wished to
stand for election to the Company Board at the Company’s 2007 Annual Meeting of Shareholders
(including any adjournments, reschedulings, continuations or postponements thereof, the “Annual
Meeting”) and requested the Company Board to withdraw his nomination for such election;

     WHEREAS, on July 1, 2007, Michael J. Willner was appointed to the Company Board to fill the
vacancy created by such resignation and, concurrently with such appointment, was named to the
Compensation Committee and the Finance and Strategic Planning Committee of the Board and was named
Vice Chairman of the Board;

     WHEREAS, on July 1, 2007, the Company Board nominated Mr. Willner to stand for election as a
director of the Company at the Annual Meeting; and

     WHEREAS, Intervoice and David Brandenburg desire to amend the Board Representation and
Governance Agreement to provide that Mr. Hammond is no longer a Brandenburg Nominee and has been
replaced for all purposes by Mr. Willner;

     NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

     Section 1. Definitions; References. Unless otherwise specifically defined herein,
each term used herein shall have the meaning assigned to such term in the Board Representation and
Governance Agreement. Each reference to “hereof”, “herein”, “hereunder”, “hereby” and “this
Agreement” shall from and after the date hereof refer to the Board Representation and Governance
Agreement as amended by this Amendment.

     Section 2. Brandenburg Nominees. Section 2.1(a) of the Board Representation and
Governance Agreement is hereby amended to provide that “Brandenburg Nominees” shall mean David W.
Brandenburg, Timothy W. Harris

1

 

and Michael J. Willner (the “Replacement Brandenburg Nominee”). All references to Daniel D.
Hammond in the Board Representation and Governance Agreement shall be amended to be deemed
references to the Replacement Brandenburg Nominee.

     Section 3. No Further Amendment. Except as otherwise provided herein, the Board
Representation and Governance Agreement shall remain unchanged and in full force and effect.

     Section 4. Effect of Amendment. From and after the execution of this Amendment by the
parties hereto, any references to the Board Representation and Governance Agreement shall be deemed
a reference to the Board Representation and Governance Agreement as amended hereby.

     Section 5. Governing Law. This Amendment shall be governed by, enforced under and
construed in accordance with the laws of the State of Texas, without giving effect to any choice or
conflict of law provision or rule thereof or of any other jurisdiction.

     Section 6. Counterparts. This Amendment may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

     Section 7. Descriptive Headings. The descriptive headings herein are inserted for
convenience of reference only and shall in no way be construed to define, limit, describe, explain,
modify, amplify, or add to the interpretation, construction or meaning of any provision of, or
scope or intent of, this Amendment or the Board Representation and Governance Agreement nor in any
way affect this Amendment or the Board Representation and Governance Agreement.

     IN WITNESS WHEREOF, each of the undersigned has caused this Amendment to be signed by its duly
authorized officer as of the date first above written.

INTERVOICE, INC.

	 	 	 	 	 
	By:

	 	/s/ Robert E. Ritchey
	 	 	 
	Name:

	 	 	 	Robert E. Ritchey
	Title:

	 	 	 	President and Chief Executive Officer
	 
	 	 	 	 
	/s/
David W. Brandenburg

	 
	David W. Brandenburg

2exv10w1

 

Exhibit 10.1

FORM OF PERFORMANCE-BASED VESTING

STOCK OPTION AGREEMENT

____________, Optionee:

     Questcor Pharmaceuticals Inc. (the “Company”), pursuant to its 2006 Equity Incentive Award
Plan (the “Plan”) has this day granted to you, the optionee named above, an option to purchase
shares of the common stock of the Company (“Common Stock”). This option [is/is not] intended to
qualify and will be treated as an “incentive stock option” within the meaning of Section 422 of the
Internal Revenue Code of 1986, as amended (the “Code”).

     The grant hereunder is in connection with and in furtherance of the Company’s compensatory
benefit plan for participation of the Company’s employees (including officers), directors or
consultants. Any capitalized term not defined herein shall have the same meaning ascribed to it in
the Plan.

The details of your option are as follows:

1. The total number of
shares of Common Stock subject to this option is ______ (___).
Subject to the limitations contained herein, this option shall vest upon the satisfaction of
certain performance criteria, which under the Plan are limited to the following: net earnings
(either before or after interest, taxes, depreciation and amortization), sales or revenue, net
income (either before or after taxes), operating earnings, cash flow (including, but not limited
to, operating cash flow and free cash flow), return on net assets, return on stockholders’ equity,
return on sales, gross or net profit margin, working capital, earnings per share and price per
share of Stock, the achievement of certain scientific milestones, customer retention rates,
licensing, partnership or other strategic transactions, execution of a corporate collaboration
agreement relating to a product candidate of the Company, acceptance by the U.S. Food and Drug
Administration (“FDA”) or a comparable foreign regulatory authority of a final New Drug Application
or similar document, approval for marketing of a product candidate of the Company by the FDA or a
comparable foreign regulatory authority, obtaining a specified level of financing for the Company,
as determined by the Committee, including through government grants (or similar awards) and the
issuance of securities, commencement of a particular stage of clinical trials for a product
candidate of the Company, or the achievement of one or more corporate, divisional or individual
scientific or inventive measures. Any of the criteria identified above may be measured either in
absolute terms or as compared to any incremental increase or as compared to results of a peer
group. Notwithstanding the foregoing, in the event of a Change in Control of the Company, then
this option shall become vested as provided in Section 12.2 of the Plan.

1

 

2. The exercise price of this option is
______ ($___) per share, being not less than the
fair market value of the Common Stock on the last trading day prior to the date of grant of this
option.

     (a) Payment of the exercise price per share is due in full in cash (including check) upon
exercise of all or any part of each installment which has become exercisable by you; provided,
however, that, if at the time of exercise the Company’s Common Stock is publicly traded and quoted
regularly in the Wall Street Journal, payment of the exercise price, to the extent permitted by
applicable statutes and regulations, may be made by delivery of already-owned shares of Common
Stock, or a combination of cash and already-owned Common Stock. Such Common Stock (i) shall be
valued at its fair market value on the date of exercise, (ii) if originally acquired from the
Company, must have been held for the period required to avoid a charge to the Company’s reported
earnings, and (iii) must be owned free and clear of any liens, claims, encumbrances or security
interests.

     (b) Notwithstanding the foregoing, this option may be exercised pursuant to a program
developed under Regulation T as promulgated by the Federal Reserve Board which results in the
receipt of cash (or check) by the Company prior to the issuance of Common Stock.

3. The minimum number of shares with respect to which this option may be exercised at any one time
is one hundred (100), except (a) as to an installment subject to exercise, as set forth in
paragraph 1, which amounts to fewer than one hundred (100) shares, in which case, as to the
exercise of that installment, the number of shares in such installment shall be the minimum number
of shares, and (b) with respect to the final exercise of this option this minimum shall not apply.
In no event may this option be exercised for any number of shares, which would require the issuance
of anything other than whole shares.

4. Notwithstanding anything to the contrary contained herein, this option may not be exercised
unless the shares issuable upon exercise of this option are then registered under the Securities
Act or, if such shares are not then so registered, the Company has determined that such exercise
and issuance would be exempt from the registration requirements of the Securities Act.

5. The term of this option commences on the date hereof and, unless sooner terminated as set forth
below or in the Plan, terminates on ______ (which date shall be no more than ten (10) years
from the date this option is granted). In no event may this option be exercised after the date on
which it terminates. This option shall terminate prior to the expiration of its term as follows:
ninety (90) calendar days after the termination of your employment with the Company or an affiliate
of the Company (as defined in the Plan) for any reason or for no reason unless:

     (a) such termination of employment is due to your permanent and total disability (within the
meaning of Section 422(c)(6) of the Code), in which event the option shall terminate on the earlier
of the termination date set forth above or twelve (12) months following such termination of
employment; or

     (b) such termination of employment is due to your death, in which event the option shall
terminate on the earlier of the termination date set forth above or twelve (12) months after your
death; or

2

 

     (c) during any part of such three (3) month period the option is not exercisable solely
because of the condition set forth in paragraph 4 above, in which event the option shall not
terminate until the earlier of the termination date set forth above or until it shall have been
exercisable for an aggregate period of three (3) months after the termination of employment; or

     (d) exercise of the option within three (3) months after termination of your employment with
the Company or with an affiliate would result in liability under section 16(b) of the Exchange Act,
in which case the option will terminate on the earlier of (i) the termination date set forth above,
(ii) the tenth (10th) day after the last date upon which exercise would result in such liability or
(iii) six (6) months and ten (10) days after the termination of your employment with the Company or
an affiliate.

     However, this option may be exercised following termination of employment only as to that
number of shares as to which it was exercisable on the date of termination of employment under the
provisions of paragraph 1 of this option. Further, if you leave the employment of the Company
before the six-month anniversary of the commencement of this Stock Option grant, then your right to
exercise this option as to any shares as to which it was otherwise exercisable prior to termination
is immediately terminated.

6. This option may be exercised, to the extent specified above, by delivering a notice of exercise
(in a form designated by the Company) together with the exercise price to the Secretary of the
Company, or to such other person as the Company may designate, during regular business hours,
together with such additional documents as the Company may then require.

     (a) By exercising this option you agree that:

          (i) the Company may require you to enter an arrangement providing for the payment by you to
the Company of any tax withholding obligation of the Company arising by reason of (1) the exercise
of this option; (2) the lapse of any substantial risk of forfeiture to which the shares are subject
at the time of exercise; or (3) the disposition of shares acquired upon such exercise; and

          (ii) you will notify the Company in writing within fifteen (15) days after the date of any
disposition of any of the shares of the Common Stock issued upon exercise of this option that
occurs within two (2) years after the date of this option grant or within one (1) year after such
shares of Common Stock are transferred upon exercise of this option.

7. This option is not transferable, except by will or by the laws of descent and distribution, and
is exercisable during your life only by you.

8. This option is not an employment contract and nothing in this option shall be deemed to create
in any way whatsoever any obligation on your part to continue in the employ of the Company, or of
the Company to continue your employment with the Company.

9. Any notices provided for in this option or the Plan shall be given in writing and shall be
deemed effectively given upon receipt or, in the case of notices delivered by the Company to you,
five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the
address
specified below or at such other address as you hereafter designate by written notice to the
Company.

3

 

10. This option is subject to all the provisions of the Plan, a copy of which is attached hereto
and its provisions are hereby made a part of this option, and this option is further subject to all
interpretations, amendments, rules and regulations which may from time to time be promulgated and
adopted pursuant to the Plan. In the event of any conflict between the provisions of this option
and those of the Plan, the provisions of the Plan shall control.

[Signature on Following Page]

Dated the ___day of ______, ___.

	 	 	 	 	 
	 	Very truly yours,

QUESTCOR PHARMACEUTICALS, INC.

 	 
	 	By	 	 
	 	 	Duly authorized on behalf 	 
	 	 	of the Board of Directors 	 
	 

The undersigned:

     (a) Acknowledges receipt of the foregoing option and the attachments referenced therein and
understands that all rights and liabilities with respect to this option are set forth in the option
and the Plan; and

     (b) Acknowledges that as of the date of grant of this option, it sets forth the entire
understanding between the undersigned optionee and the Company and its affiliates regarding the
acquisition of stock in the Company and supersedes all prior oral and written agreements on that
subject with the exception of the following agreements only:

	 	 	 	 	 	 	 	 	 
	 
	 	NONE	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	(Initial)	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	OTHER	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

	 	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	Optionee	 	 
	 
	 	 	 	 
	Address:

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	SS# / Tax I.D.#
	 	 	 	 
	 

	 	 	 	 

4

 

Attachments:

     Form of Exercise

5

 

NOTICE OF EXERCISE

Date of Exercise: _________

Questcor Pharmaceuticals, Inc.

3260 Whipple Road

Union City, California 94587

Ladies and Gentlemen:

     This constitutes notice under my stock option that I elect to purchase the number of shares
for the price set forth below.

	 	 	 	 	 	 	 	 	 
	Type of option (check one)	 	 	 	 	 	Incentive ___   Nonstatutory ___
	 
	 	 	 	 	 	 	 	 
	Stock option dated

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Stock option grant ID#
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Number of shares as
to which option is
exercised:
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Certificates to be
issued in name of:
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Total exercise price:

	 	 	$	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	+Cash payment delivered 

herewith:

	 	 	$	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 

 

			
	+	 	All checks must be made payable to “Questcor Pharmaceuticals Inc.”

By this exercise, I agree (i) to provide such additional documents as you may require pursuant to
the terms of the 2006 Equity Incentive Award Plan, (ii) to provide for the payment by me to you (in
the manner designated by you) of your withholding obligation, if any, relating to the exercise of
this option, and (iii) if this exercise relates to an incentive stock option, to notify you in
writing within fifteen (15) days after the date of any disposition of any shares of Common Stock
issued upon exercise of this option that occurs within two (2) years after the date of grant of
this option or within one (1) year after such shares of Common Stock are issued upon exercise of
this option.

	 	 	 	 	 
	 	Very truly yours,

 	 
	 	 	 
	 	 	 
	 	 	 
	 

1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]